

CHAPTER ONE: INTRODUCTION.....	1
STUDY GOALS AND OBJECTIVES.....	1
REASONS FOR DOING THE STUDY	1
SCOPE OF REPORT	1
INTENDED AUDIENCE.....	2
METHODOLOGY	2
RELATED BCC STUDIES	2
ANALYST CREDENTIALS.....	3
BCC ONLINE SERVICES.....	3
DISCLAIMER	3
 CHAPTER TWO: SUMMARY.....	 4
SUMMARY.....	4
<i>SUMMARY TABLE GLOBAL MARKET FOR CELL-BASED ASSAYS, THROUGH 2015 (\$ MILLIONS)</i>	<i>5</i>
<i>SUMMARY FIGURE GLOBAL MARKET FOR CELL-BASED ASSAYS, 2009–2015 (\$ MILLIONS)</i>	<i>5</i>
 CHAPTER THREE: OVERVIEW	 6
DRUG DISCOVERY	6
<i>FIGURE 1 DRUG DISCOVERY AND STEPS</i>	<i>6</i>
<i>TABLE 1 CELL-BASED ASSAYS AND USES</i>	<i>7</i>
HIGH CONTENT SCREENING (HCS) INSTRUMENTATION AND SOFTWARE	7
DATA ANALYSIS	8
OVERVIEW—CELL-BASED ASSAYS	9
OVERVIEW—CELL-BASED ASSAYS (CONTINUED).....	10
OVERVIEW—CELL-BASED ASSAYS (CONTINUED).....	11
TOOLS EMERGING TO AID THE AREA OF DRUG DISCOVERY	12
TOOLS EMERGING TO AID THE ... (CONTINUED).....	13
HIGH CONTENT IMAGING.....	14
High Content Imaging (Continued)	15
CELL-BASED SCREENING	16
HISTORY OF HIGH-CONTENT SCREENING	17
TYPES OF CELL-BASED ASSAYS.....	18
TYPES OF TISSUE CULTURE ASSAYS.....	18
PROLIFERATION ASSAYS	18
WST (tetrazolium salt based) Reagents	18
Alamar Blue Colorimetric Assay	19
<i>TABLE 2 TYPES OF CELL-BASED ASSAYS</i>	<i>19</i>
APOPTOSIS ASSAYS	19
Caspase Assays.....	20
DNA Fragmentation Assays	21
Annexin V and Cell Permeability Assays.....	21

Mitochondrial Assays	22
Other Assays.....	22
ASSAYS TO MEASURE GENE EXPRESSION	23
ACTIVATION ASSAYS.....	23
ASSAY PROOF OF CONCEPT FOR CELL-BASED ASSAYS	23
<i>TABLE 3 ASSAY PROOF OF CONCEPT FOR CELL--BASED ASSAYS</i>	<i>23</i>
<i>TABLE 3 (CONTINUED).....</i>	<i>24</i>
CELL-BASED ASSAYS AND TECHNOLOGY TRENDS.....	24
WHY CELL-BASED APPROACHES?.....	25
<i>In Vitro</i> Homogeneous Assays.....	25
Cell-Based Reporter Assays	26
CELL-BASED ASSAYS AND FUTURE GROWTH	26
<i>TABLE 4 GLOBAL MARKET AND FORECAST FOR CELL--BASED</i>	
<i>ASSAYS, THROUGH 2015 (\$ MILLIONS).....</i>	<i>27</i>
<i>FIGURE 2 GLOBAL MARKET AND FORECAST FOR CELL-BASED</i>	
<i>ASSAYS, 2009–2015 (\$ MILLIONS).....</i>	<i>27</i>
CELL-BASED ASSAYS FOR GPCRS.....	28
IMMORTALIZED CELLS AND HTS	28
IMMORTALIZED CELLS AND HTS (CONTINUED)	29
FUTURE.....	30
PRIMARY, STEM CELLS, AND HIGH-THROUGHPUT SCREENING	30
PRIMARY, STEM CELLS, ... (CONTINUED)	31
STEM CELLS AND CELL-BASED ASSAYS	32
Embryonic Stem and Cell-based Assays.....	33
PRIMARY CELLS, STEM CELLS, AND HIGH-THROUGHPUT	
IMAGING.....	34
ADVANTAGES OF MULTIPLEXED BIOLOGICAL ASSAYS	34
CELL-BASED APPROACHES FOR ADME/TOX SCREENING.....	34
Cell-Based Approaches for ... (Continued)	35
Cell-Based Approaches for ... (Continued)	36
MARKET OPPORTUNITY	37
<i>TABLE 5 ADME AND TOXICITY SCREENING MARKET AND</i>	
<i>FORECAST, THROUGH 2015 (\$ MILLIONS).....</i>	<i>37</i>
<i>FIGURE 3 ADME AND TOXICITY SCREENING MARKET AND</i>	
<i>FORECAST, 2009-2015 (\$ MILLIONS).....</i>	<i>38</i>
ADME and Toxicity Screening.....	38
<i>TABLE 6 BIOLOGICAL ASSAY SYSTEMS FOR THE EVALUATION OF</i>	
<i>CYTOCHROME P450 ENZYME ISOFORMS</i>	<i>39</i>
<i>TABLE 6 (CONTINUED).....</i>	<i>40</i>
ADME and Toxicity ... (Continued)	41
<i>TABLE 7 HEPATOCYTE ASSAY SYSTEMS</i>	<i>42</i>
<i>TABLE 8 ADME ASSAYS</i>	<i>42</i>
<i>TABLE 9 COMMON TOXICITY ASSAYS.....</i>	<i>43</i>
Optical Oxygen Sensors.....	43

Characterized Cell Lines for Cell-Based ADME and Toxicity Screening	43
MULTIPLEXED CELL-BASED ASSAYS	44
COMPOUND EFFECTS ON CELLS	45
CELL-BASED BIOLOGICAL ASSAYS	46
CELL-BASED BIOLOGICAL ASSAYS (CONTINUED).....	47
GENERAL BIOASSAY GUIDANCE.....	48
HIGH-THROUGHPUT IMAGING-BASED PLATFORM FOR CELL- BASED ASSAYS.....	48
CELL ASSAYS IN TODAY'S DRUG-DISCOVERY PROCESS.....	49
CELL ASSAYS IN TODAY'S ...(CONTINUED).....	50
CELL ASSAYS IN TODAY'S ...(CONTINUED).....	51
LABEL-FREE CELLULAR ASSAYS: THE RELEVANT FUTURE OF DRUG DISCOVERY	52
LABEL-FREE ASSAYS AND APPLICATIONS	53
BENEFITS OF LABEL-FREE ASSAYS	53
<i>TABLE 10 LABEL-FREE ASSAYS AND APPLICATIONS</i>	<i>54</i>
ADVANTAGES AND FUTURE.....	54
Advantages and Future (Continued)	55
MAJOR CHALLENGES FOR ADOPTION OF LABEL-FREE TECHNOLOGY.....	56
CONCLUSIONS.....	56
CONCLUSIONS (CONTINUED)	57
CHAPTER FOUR: TECHNOLOGIES	58
FACTORS FOR CELL-BASED ASSAY DEVELOPMENT.....	58
<i>TABLE 11 FACTORS FOR CELL-BASED ASSAY DEVELOPMENT</i>	<i>59</i>
<i>TABLE 11 (CONTINUED).....</i>	<i>60</i>
REPORTER GENE TECHNOLOGY.....	61
Reporter Gene Technology (Continued).....	62
<i>TABLE 12 MAIN FEATURES OF THE DIFFERENT APPROACHES TO CELL-BASED SYSTEMS AVAILABLE FOR DRUG SCREENING</i>	<i>63</i>
CELL-BASED ASSAYS FOR STUDYING OF PROTEIN- PROTEIN INTERACTIONS	63
CELL-BASED PROTEIN-FRAGMENT COMPLEMENTATION ASSAYS.....	64
MEASURING CALCIUM SIGNALING.....	65
CELL-BASED LABEL-FREE APPROACHES	65
AUTOMATION AND MINIATURIZATION.....	66
CELL PATTERNING.....	67
CELL-BASED ASSAYS AND PHYSIOLOGICAL RELEVANCE	68
CELL-BASED ASSAYS AND MULTIPLEXING.....	68
DEVELOPING REPORTER ASSAYS.....	69
REPORTER ASSAYS AND MULTIPLEXING	69
ULTRAHIGH-THROUGHPUT SCREENING	70

ULTRAHIGH-THROUGHPUT SCREENING (CONTINUED)	71
DEVELOPMENT OF PATHHUNTER ASSAY	72
HIGH CONTENT SCREENING TECHNOLOGY	72
TABLE 13 CURRENT CONFOCAL PLATFORMS	73
TABLE 14 WIDEFIELD HCS PLATFORMS	73
IMAGING CELLS FOR CELL-BASED ASSAYS	74
MICROSCOPIC VISUALIZATION OF CELLS	75
QUANTUM DOTS	75
LABEL-FREE IMAGING	76
ADME IN DRUG DEVELOPMENT	77
TABLE 15 ADME STUDIES FOR FILING AN IND	78
TABLE 16 ADME STUDIES FOR CLINICAL FILINGS	79
ROLE OF ADME IN DRUG DESIGN	79
ROLE OF ADME IN DRUG DESIGN (CONTINUED)	80
PRODRUG STRATEGIES	81
MOLECULAR MODELING	82
SUMMARY	83
LIMITATIONS OF THE USE OF CELL-BASED ASSAYS IN THE PROCESS OF RISK ASSESSMENT	83
Limitations of the Use ... (Continued)	84
BOTTLENECKS IN CELL-BASED SCREENING	85
METHODS TO IMPROVE THROUGHPUT IN CELL-BASED ASSAYS	86
NEWER TECHNOLOGIES	87
SOLIDUS BIOSCIENCES	87
SRU BIOSYSTEMS	87
SIMUGEN	88
MINIATURIZATION OF BIOLOGICAL ASSAYS—OVERVIEW ON MICROWELL DEVICES FOR SINGLE-CELL ANALYSES	88
MICROFLUIDIC CELL-CULTURE SYSTEMS FOR DRUG RESEARCH	89
CONCLUSION	90
CHAPTER FIVE: COMMERCIALIZATION OF CELL-BASED ASSAYS	91
CELL-BASED ASSAYS FOR DRUG DISCOVERY	91
THE PARADIGM OF DRUG DISCOVERY AND CELL-BASED ASSAYS	91
OPPORTUNITIES FOR MARKET ADOPTION	91
Opportunities for Market Adoption (Continued)	92
TABLE 17 BIOLOGICAL APPLICATIONS FOR HCA	93
Measuring Cell Proliferation	94
Roche Applied Science	95
BioVision	95
Promega	95
Millipore	96

Toward Therapies with Stem and Immune Cells	96
Cell-Based Screening Assays	97
Euroscreen.....	97
Arena Pharmaceuticals	98
Norak Biosciences	98
Orphan Receptors	99
Orphan Receptors (Continued).....	100
SUMMARY	101
CHAPTER SIX: MARKET.....	102
THE CELL-BASED ASSAYS MARKET	102
MARKET OVERVIEW	103
<i>TABLE 18 THE GLOBAL DRUG-DISCOVERY TECHNOLOGIES</i>	
<i>MARKET, THROUGH 2015 (\$ MILLIONS)</i>	104
<i>FIGURE 4 THE GLOBAL DRUG-DISCOVERY TECHNOLOGIES</i>	
<i>MARKET, 2009-2015 (\$ MILLIONS)</i>	105
CELL-BASED ASSAYS	106
<i>TABLE 19 GLOBAL MARKET FOR CELL-BASED ASSAYS, THROUGH</i>	
<i>2015 (\$ MILLIONS)</i>	106
<i>FIGURE 5 GLOBAL MARKET FOR CELL-BASED ASSAYS, 2009–2015</i>	
<i>(\$ MILLIONS)</i>	107
MARKET NEED.....	107
<i>TABLE 20 LIMITATIONS OF CELL-BASED ASSAYS</i>	108
Cell-Based Assays—General Assays	108
<i>TABLE 21 CELL-BASED GENERAL ASSAYS MARKET, 2009 (\$</i>	
<i>MILLIONS)</i>	109
Specialized Cell-Based Assays	109
<i>TABLE 22 CELL-BASED SPECIALIZED ASSAYS MARKET, 2009 (\$</i>	
<i>MILLIONS)</i>	109
<i>FIGURE 6 CELL-BASED SPECIALIZED ASSAYS MARKET, 2009 (\$</i>	
<i>MILLIONS)</i>	109
Functional Cell Assays	110
<i>TABLE 23 KEY COMPANIES</i>	111
Cell Migration Assays	111
USE OF CELL-BASED ASSAYS	112
<i>TABLE 24 TOTAL HIGH CONTENT SCREENING MARKET</i>	
<i>FORECAST, THROUGH 2015 (\$ MILLIONS)</i>	113
<i>FIGURE 7 TOTAL HIGH CONTENT SCREENING MARKET</i>	
<i>FORECAST, 2009-2015 (\$ MILLIONS)</i>	113
High-Content Screening Instrumentation	114
High Content Screening Kits	115
High Content Screening (HCS) Instrumentation Market	116
<i>TABLE 25 HIGH CONTENT SCREENING INSTRUMENTATION</i>	
<i>MARKET FORECAST, THROUGH 2015 (\$ MILLIONS)</i>	117

<i>FIGURE 8 HIGH CONTENT SCREENING INSTRUMENTATION</i>	
<i>MARKET FORECAST, 2009-2015 (\$ MILLIONS)</i>	117
CHALLENGES FOR CELL-BASED ASSAYS IN THE MARKET	
PLACE	118
Cell-Based Assays and Drug-discovery Market	119
Drug-discovery Technologies Market	119
<i>TABLE 26 GLOBAL MARKET FOR CELL-BASED ASSAYS FOR DRUG</i>	
<i>DISCOVERY, THROUGH 2015 (\$ MILLIONS)</i>	120
<i>FIGURE 9 GLOBAL MARKET FOR CELL-BASED ASSAYS FOR DRUG</i>	
<i>DISCOVERY, 2009–2015 (\$ MILLIONS)</i>	121
DRUG-DISCOVERY TECHNOLOGIES	121
Key Companies	122
ADME and Toxicology Market	122
<i>TABLE 27 GLOBAL MARKET FOR CELL-BASED ASSAYS FOR ADME,</i>	
<i>THROUGH 2015 (\$ MILLIONS)</i>	123
<i>FIGURE 10 GLOBAL MARKET FOR CELL-BASED ASSAYS FOR</i>	
<i>ADME, 2009–2015 (\$ MILLIONS)</i>	123
<i>In Vitro</i> Predictive Toxicology	124
<i>TABLE 28 IN VITRO PREDICTIVE TOXICOLOGY ASSAYS</i>	124
ADME: Tools and Technologies	125
ADME Studies for FDA Submissions	125
Key Companies	126
CELL-BASED ASSAYS FOR RESEARCH PURPOSES	126
CELL-BASED ASSAYS AND G-PROTEIN-COUPLED	
RECEPTORS (GPCRS)	127
<i>TABLE 29 GPCR-TARGETING DRUGS</i>	127
Omeros—a GPCR Drug Developing Company	128
GPCRs—a Potent Class of Drug Targets	128
GPCRs—a Potent Class ... (Continued)	129
<i>TABLE 30 ASSAY METHODS TO STUDY GPCRS</i>	130
<i>TABLE 31 GPCR PRIMARY SCREENING ASSAYS</i>	130
<i>TABLE 32 GLOBAL MARKET FOR GPCR SCREENING AND</i>	
<i>PROFILING, 2010 (\$ MILLIONS)</i>	131
Companies and Technologies	131
Key Companies	132
<i>TABLE 33 KEY PLAYERS IN THE GPCR SPACE</i>	132
Cisbio	133
PerkinElmer	133
Multispan	134
Codex Biosolutions	134
ChanTest	135
Corning Life Sciences	135
GPCR Drugs	135
Cell-based Assays and Screening Ion Channels	136

Label-free Detection	136
Label-free Detection (Continued)	137
Key Cell-Based Assays Players	138
Life Technologies (Invitrogen Corporation)	138
<i>TABLE 34 INVITROGEN'S CELL--BASED TECHNOLOGIES</i>	<i>138</i>
CellSensor Assays	139
LanthaScreen Assays	139
Results of Operations.....	139
<i>TABLE 35 COMPARISON OF YEARS ENDED DECEMBER 31, 2010</i> <i>AND 2009 (\$ MILLIONS)</i>	<i>140</i>
Molecular Devices	140
Roche	141
Thermo Fisher Scientific	141
<i>TABLE 36 THERMO FISHER-REVENUE, 2009 AND 2010 (\$</i> <i>MILLIONS)</i>	<i>142</i>
CONCLUSION	142
 CHAPTER SEVEN: GLOBAL MARKET AND GROWTH	 143
WORLDWIDE MARKET FOR CELL-BASED ASSAYS.....	143
<i>TABLE 37 GLOBAL MARKET FOR CELL-BASED ASSAYS, BY</i> <i>GEOGRAPHICAL REGION, THROUGH 2015 (\$ MILLIONS)</i>	<i>143</i>
<i>FIGURE 11 GLOBAL MARKET FOR CELL-BASED ASSAYS-BY</i> <i>GEOGRAPHICAL REGION, 2009-2015 (\$ MILLIONS)</i>	<i>144</i>
EMERGING ECONOMIES	144
U.S. MARKET	145
<i>TABLE 38 U.S. MARKET FOR CELL-BASED ASSAYS, THROUGH 2015</i> <i>(\$ MILLIONS)</i>	<i>146</i>
<i>FIGURE 12 U.S. MARKET FOR CELL-BASED ASSAYS, 2009-2015 (\$</i> <i>MILLIONS)</i>	<i>146</i>
MARKET OVERVIEW	146
European Market.....	147
European Market (Continued)	148
<i>TABLE 39 EUROPEAN CELL-BASED ASSAY MARKET FORECAST,</i> <i>THROUGH 2015 (\$ MILLIONS)</i>	<i>149</i>
<i>FIGURE 13 EUROPEAN CELL-BASED ASSAY MARKET FORECAST,</i> <i>2009-2015 (\$ MILLIONS)</i>	<i>149</i>
<i>TABLE 40 EUROPEAN CELL-BASED ASSAY KITS MARKET</i> <i>FORECAST, THROUGH 2015 (\$ MILLIONS)</i>	<i>150</i>
<i>FIGURE 14 EUROPEAN CELL-BASED ASSAY KITS MARKET</i> <i>FORECAST, 2009-2015 (\$ MILLIONS)</i>	<i>150</i>
Emerging Economies	151
Drug Discovery in India and China	151
China	151
<i>TABLE 41 CHINA DRUG-DISCOVERY OUTSOURCING MARKET</i> <i>FORECAST, THROUGH 2015 (\$ MILLIONS)</i>	<i>152</i>

<i>FIGURE 15 CHINA DRUG-DISCOVERY OUTSOURCING MARKET FORECAST 2009-2015 (\$ MILLIONS)</i>	153
Challenges.....	153
India	154
<i>TABLE 42 INDIAN DRUG-DISCOVERY MARKET FORECAST, THROUGH 2015 (\$ MILLIONS)</i>	154
<i>FIGURE 16 INDIAN DRUG-DISCOVERY MARKET FORECAST, 2009-2015 (\$ MILLIONS)</i>	155
The Indian Pharma Industry—Looking Beyond	
Generics	155
In-licensing and Custom Manufacturing.....	156
Biosimilars	156
Next Steps—the Drug-discovery Outsourcing Market.....	156
ADVANCES IN CELL-BASED ASSAYS	157
Outlook.....	158
Outlook (Continued)	159
CHAPTER EIGHT: KEY COMPANIES	160
KEY COMPANIES OUTLINED	160
BD BIOSCIENCES	161
BECKMAN COULTER.....	161
CALIPER LIFE SCIENCES (CORPORATE HEADQUARTERS)	162
CROS AND CELL-BASED ASSAYS	163
<i>TABLE 43 CROS AND CELL-BASED ASSAYS</i>	163
<i>TABLE 43 (CONTINUED)</i>	164
CYSBIO	164
DISCOVERX.....	165
EVOTEC AG (HEADQUARTERS).....	166
GE HEALTHCARE	166
INVITROGEN CORPORATION	166
LONZA.....	167
MILLIPORE	168
MOLECULAR DEVICES (DANAHER)	168
ONCOIMMUNIN	168
ORIGENE.....	169
PERKIN ELMER	169
PROMEGA CORPORATION.....	169
Promega Corporation (Continued).....	170
STEMCELLS.....	171
THERMO FISHER SCIENTIFIC.....	171
TTP LABTECH	172
CHAPTER NINE: LEGAL ASPECTS OF CELL-BASED ASSAYS	173

THE INTELLECTUAL PROPERTY LANDSCAPE FOR CELL-BASED ASSAYS.....	173
THE INTELLECTUAL PROPERTY...(CONTINUED).....	174
LATEST NEWS, ALLIANCES, AND MERGERS—2010.....	175
Vivo Biosciences, ACEA Biosciences, and Roche to Develop New xCELLigence System Assays for Stem Cell and Cancer Research.....	175
Roche	176
DiscoverX Corporation Acquires KINOMEscan, Previously Part of Ambit Biosciences.....	177
Promega and Celsis <i>In Vitro</i> Technologies to Offer More Reliable Solutions for ADME/Tox Testing in Primary Hepatocytes	177
Promega and Celsis <i>In Vitro</i> ...(Continued)	178
Lonza Acquired Vivante GMP, a Viral-vaccine and Gene Therapy Company Based in Houston.....	179
Vitro Expands HemoGenix Alliance to Include Cell-Based Testing for Liver Toxicity.....	179
Tools for Stem Cell and Drug Development	180
MERGERS	181
Ligand and Neurogen Amend Merger Agreement.....	181
Platypus Licenses Cell Exclusion Zone Technology to Cell Biolabs	182
Ion Channel and GPCR Screening Services and Products on March 21, 2011	182
Label-Free Technologies.....	182
PerkinElmer Launches the EnSpire Multimode Plate Reader with Label-free Detection Technology for Drug-discovery Research	183
SUMMARY AND OUTLOOK	184
Summary and Outlook (Continued).....	185
BIBLIOGRAPHY	186
BIBLIOGRAPHY	186
BIBLIOGRAPHY (CONTINUED)	187
BIBLIOGRAPHY (CONTINUED)	188